메뉴 건너뛰기




Volumn 79, Issue 7, 2004, Pages 899-903

Thalidomide: Tragic past and promising future

Author keywords

[No Author keywords available]

Indexed keywords

LENALIDOMIDE; THALIDOMIDE;

EID: 3042735762     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/79.7.899     Document Type: Note
Times cited : (74)

References (83)
  • 3
    • 0023789803 scopus 로고
    • A short history of thalidomide embryopathy
    • Lenz W. A short history of thalidomide embryopathy. Teratology. 1988;38:203-215.
    • (1988) Teratology , vol.38 , pp. 203-215
    • Lenz, W.1
  • 4
    • 0026453406 scopus 로고
    • A personal perspective on the thalidomide tragedy
    • Lenz W. A personal perspective on the thalidomide tragedy. Teratology. 1992;46:417-418.
    • (1992) Teratology , vol.46 , pp. 417-418
    • Lenz, W.1
  • 5
    • 49749219257 scopus 로고
    • Thalidomide and congenital abnormalities
    • Lenz W. Thalidomide and congenital abnormalities [letter]. Lancet. 1962;1:45.
    • (1962) Lancet , vol.1 , pp. 45
    • Lenz, W.1
  • 6
    • 47349113508 scopus 로고
    • Thalidomide and congenital abnormalities
    • McBride WG. Thalidomide and congenital abnormalities [letter]. Lancet. 1961;2:1358.
    • (1961) Lancet , vol.2 , pp. 1358
    • McBride, W.G.1
  • 8
    • 3042800237 scopus 로고
    • Thalidomide and congenital abnormalities
    • Burley DM. Thalidomide and congenital abnormalities [letter]. Lancet. 1962;1:100-101.
    • (1962) Lancet , vol.1 , pp. 100-101
    • Burley, D.M.1
  • 9
    • 50549164591 scopus 로고
    • Thalidomide and congenital abnormalities
    • Rogerson G. Thalidomide and congenital abnormalities [letter]. Lancet. 1962;1:691.
    • (1962) Lancet , vol.1 , pp. 691
    • Rogerson, G.1
  • 10
    • 0004043605 scopus 로고
    • Thalidomide
    • Woodyatt PB. Thalidomide [letter]. Lancet. 1962;1:750.
    • (1962) Lancet , vol.1 , pp. 750
    • Woodyatt, P.B.1
  • 11
    • 84883832143 scopus 로고
    • Clinical experience with thalidomide in patients with cancer
    • Grabstad H, Golbey R. Clinical experience with thalidomide in patients with cancer. Clin Pharmacol Ther. 1965;6:298-302.
    • (1965) Clin Pharmacol Ther , vol.6 , pp. 298-302
    • Grabstad, H.1    Golbey, R.2
  • 13
    • 84883833410 scopus 로고
    • Thalidomide in the treatment of lepra reactions
    • Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther. 1965;6:303-306.
    • (1965) Clin Pharmacol Ther , vol.6 , pp. 303-306
    • Sheskin, J.1
  • 14
    • 0015189572 scopus 로고
    • WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients
    • Iyer CG, Languillon J, Ramanujam K, et al. WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull World Health Organ. 1971;45:719-732.
    • (1971) Bull World Health Organ , vol.45 , pp. 719-732
    • Iyer, C.G.1    Languillon, J.2    Ramanujam, K.3
  • 15
    • 0018776006 scopus 로고
    • Thalidomide in the treatment of recurrent, necrotic, and giant mucocutaneous aphthae and aphthosis
    • Mascaro JM, Lecha M, Torras H. Thalidomide in the treatment of recurrent, necrotic, and giant mucocutaneous aphthae and aphthosis [letter]. Arch Dermatol. 1979;115:636-637.
    • (1979) Arch Dermatol , vol.115 , pp. 636-637
    • Mascaro, J.M.1    Lecha, M.2    Torras, H.3
  • 16
    • 0023852528 scopus 로고
    • Successful treatment with thalidomide of acute graft-versus-host disease after bone-marrow transplantation
    • Lim SH, McWhannell A, Vora AJ, Boughton BJ. Successful treatment with thalidomide of acute graft-versus-host disease after bone-marrow transplantation [letter]. Lancet. 1988;1:117.
    • (1988) Lancet , vol.1 , pp. 117
    • Lim, S.H.1    McWhannell, A.2    Vora, A.J.3    Boughton, B.J.4
  • 17
    • 0023870423 scopus 로고
    • Thalidomide for graft-versus-host disease after bone marrow transplantation
    • Saurat JH, Camenzind M, Helg C, Chapuis B. Thalidomide for graft-versus-host disease after bone marrow transplantation [letter]. Lancet. 1988;1:359.
    • (1988) Lancet , vol.1 , pp. 359
    • Saurat, J.H.1    Camenzind, M.2    Helg, C.3    Chapuis, B.4
  • 19
    • 0023945118 scopus 로고
    • Combination low-dose thalidomide and cyclosporine prophylaxis for acute graft-versus-host disease in a rat mismatched model
    • Vogelsang GB, Wells MC, Santos GW, Chen TL, Hess AD. Combination low-dose thalidomide and cyclosporine prophylaxis for acute graft-versus-host disease in a rat mismatched model. Transplant Proc. 1988;20(2, suppl 2):226-228.
    • (1988) Transplant Proc , vol.20 , Issue.2 SUPPL. 2 , pp. 226-228
    • Vogelsang, G.B.1    Wells, M.C.2    Santos, G.W.3    Chen, T.L.4    Hess, A.D.5
  • 20
    • 0023801340 scopus 로고
    • Thalidomide for severe acute graft-versus-host disease
    • Ringden O, Aschan J, Westerberg L. Thalidomide for severe acute graft-versus-host disease [letter]. Lancet. 1988;2:568.
    • (1988) Lancet , vol.2 , pp. 568
    • Ringden, O.1    Aschan, J.2    Westerberg, L.3
  • 21
    • 0024600080 scopus 로고
    • Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody
    • Youle M, Clarbour J, Farthing C, et al. Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. BMJ. 1989;298:432.
    • (1989) BMJ , vol.298 , pp. 432
    • Youle, M.1    Clarbour, J.2    Farthing, C.3
  • 22
    • 0029800251 scopus 로고    scopus 로고
    • Effects of thalidomide on HIV-associated wasting syndrome: A randomized, double-blind, placebo-controlled clinical trial
    • Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, et al. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS. 1996;10:1501-1507.
    • (1996) AIDS , vol.10 , pp. 1501-1507
    • Reyes-Teran, G.1    Sierra-Madero, J.G.2    Martinez Del Cerro, V.3
  • 23
    • 0026080801 scopus 로고
    • Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
    • Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991;173:699-703.
    • (1991) J Exp Med , vol.173 , pp. 699-703
    • Sampaio, E.P.1    Sarno, E.N.2    Galilly, R.3    Cohn, Z.A.4    Kaplan, G.5
  • 24
    • 0027230553 scopus 로고
    • Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation
    • Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993;177:1675-1680.
    • (1993) J Exp Med , vol.177 , pp. 1675-1680
    • Moreira, A.L.1    Sampaio, E.P.2    Zmuidzinas, A.3    Frindt, P.4    Smith, K.A.5    Kaplan, G.6
  • 25
    • 84900378551 scopus 로고
    • Thalidomide, the FDA, and us - What do you have?
    • Winter
    • Thalidomide, the FDA, and us - what do you have? Notes From the Underground: the PWA Health Group Newsletter. Winter 1995. Available at: www.aidsinfonyc.org/pwahg/notes/29.html. Accessibility verified May 14, 2004.
    • (1995) Notes from the Underground: the PWA Health Group Newsletter
  • 26
    • 0035203218 scopus 로고    scopus 로고
    • Thalidomide: 40 Years on
    • Diggle GE. Thalidomide: 40 years on. Int J Clin Pract. 2001;55:627-631.
    • (2001) Int J Clin Pract , vol.55 , pp. 627-631
    • Diggle, G.E.1
  • 27
    • 0032922147 scopus 로고    scopus 로고
    • S.T.E.P.S.: A comprehensive program for controlling and monitoring access to thalidomide
    • Zeldis JB, Williams BA, Thomas SD, Elsayed ME. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther. 1999;21:319-330.
    • (1999) Clin Ther , vol.21 , pp. 319-330
    • Zeldis, J.B.1    Williams, B.A.2    Thomas, S.D.3    Elsayed, M.E.4
  • 29
    • 0032976445 scopus 로고    scopus 로고
    • Thalidomide and the Titanic: Reconstructing the technology tragedies of the twentieth century
    • Annas GJ, Elias S. Thalidomide and the Titanic: reconstructing the technology tragedies of the twentieth century. Am J Public Health. 1999;89:98-101.
    • (1999) Am J Public Health , vol.89 , pp. 98-101
    • Annas, G.J.1    Elias, S.2
  • 30
    • 85013312416 scopus 로고
    • Tumor angiogenesis: Therapeutic implications
    • Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
    • (1971) N Engl J Med , vol.285 , pp. 1182-1186
    • Folkman, J.1
  • 31
    • 0024547916 scopus 로고
    • Successful treatment of an angiogenic disease
    • Folkman J. Successful treatment of an angiogenic disease [editorial]. N Engl J Med. 1989;320:1211-1212.
    • (1989) N Engl J Med , vol.320 , pp. 1211-1212
    • Folkman, J.1
  • 32
    • 84975525035 scopus 로고
    • Seminars in Medicine of the Beth Israel Hospital, Boston: Clinical applications of research on angiogenesis
    • Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston: clinical applications of research on angiogenesis. N Engl J Med. 1995;333:1757-1763.
    • (1995) N Engl J Med , vol.333 , pp. 1757-1763
    • Folkman, J.1
  • 33
    • 0029944122 scopus 로고    scopus 로고
    • Angiostatin induces and sustains dormancy of human primary tumors in mice
    • O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. 1996;2:689-692.
    • (1996) Nat Med , vol.2 , pp. 689-692
    • O'Reilly, M.S.1    Holmgren, L.2    Chen, C.3    Folkman, J.4
  • 34
    • 0031469819 scopus 로고    scopus 로고
    • Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
    • Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997;390:404-407.
    • (1997) Nature , vol.390 , pp. 404-407
    • Boehm, T.1    Folkman, J.2    Browder, T.3    O'Reilly, M.S.4
  • 35
    • 0031454617 scopus 로고    scopus 로고
    • Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
    • O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277-285.
    • (1997) Cell , vol.88 , pp. 277-285
    • O'Reilly, M.S.1    Boehm, T.2    Shing, Y.3
  • 36
    • 0032524068 scopus 로고    scopus 로고
    • The power of the front page of The New York Times
    • Marshall E. The power of the front page of The New York Times. Science. 1998;280:996-997.
    • (1998) Science , vol.280 , pp. 996-997
    • Marshall, E.1
  • 38
    • 0031171663 scopus 로고    scopus 로고
    • Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization
    • Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res. 1997;64:971-978.
    • (1997) Exp Eye Res , vol.64 , pp. 971-978
    • Kenyon, B.M.1    Browne, F.2    D'Amato, R.J.3
  • 39
    • 0032748385 scopus 로고    scopus 로고
    • Antitumor activity of thalidomide in refractory multiple myeloma
    • Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma [published correction appears in N Engl J Med. 2000;342:364]. N Engl J Med. 1999;341:1565-1571.
    • (1999) N Engl J Med , vol.341 , pp. 1565-1571
    • Singhal, S.1    Mehta, J.2    Desikan, R.3
  • 40
    • 0032748385 scopus 로고    scopus 로고
    • published correction appears
    • Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma [published correction appears in N Engl J Med. 2000;342:364]. N Engl J Med. 1999;341:1565-1571.
    • (2000) N Engl J Med , vol.342 , pp. 364
  • 41
    • 0033815863 scopus 로고    scopus 로고
    • Thalidomide in the treatment of relapsed multiple myeloma
    • Rajkumar SV, Fonseca R, Dispenzieri A, et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc. 2000;75:897-901.
    • (2000) Mayo Clin Proc , vol.75 , pp. 897-901
    • Rajkumar, S.V.1    Fonseca, R.2    Dispenzieri, A.3
  • 42
    • 0037216068 scopus 로고    scopus 로고
    • Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma
    • Kumar S, Gertz MA, Dispenzieri A, et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc. 2003;78:34-39.
    • (2003) Mayo Clin Proc , vol.78 , pp. 34-39
    • Kumar, S.1    Gertz, M.A.2    Dispenzieri, A.3
  • 43
    • 0033785490 scopus 로고    scopus 로고
    • A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma
    • Rajkumar SV, Witzig TE. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev. 2000;26:351-362.
    • (2000) Cancer Treat Rev , vol.26 , pp. 351-362
    • Rajkumar, S.V.1    Witzig, T.E.2
  • 44
    • 0036843032 scopus 로고    scopus 로고
    • Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma
    • Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;20:4319-4323.
    • (2002) J Clin Oncol , vol.20 , pp. 4319-4323
    • Rajkumar, S.V.1    Hayman, S.2    Gertz, M.A.3
  • 45
    • 17944376919 scopus 로고    scopus 로고
    • Thalidomide for previously untreated indolent or smoldering multiple myeloma
    • Rajkumar SV, Dispenzieri A, Fonseca R, et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia. 2001;15:1274-1276.
    • (2001) Leukemia , vol.15 , pp. 1274-1276
    • Rajkumar, S.V.1    Dispenzieri, A.2    Fonseca, R.3
  • 46
    • 0037396605 scopus 로고    scopus 로고
    • Thalidomide as initial therapy for early-stage myeloma
    • Rajkumar SV, Gertz MA, Lacy MQ, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia. 2003;17:775-779.
    • (2003) Leukemia , vol.17 , pp. 775-779
    • Rajkumar, S.V.1    Gertz, M.A.2    Lacy, M.Q.3
  • 47
    • 0037208595 scopus 로고    scopus 로고
    • Thalidomide alone or with dexamethasone for previously untreated multiple myeloma
    • Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21:16-19.
    • (2003) J Clin Oncol , vol.21 , pp. 16-19
    • Weber, D.1    Rankin, K.2    Gavino, M.3    Delasalle, K.4    Alexanian, R.5
  • 48
    • 0036322185 scopus 로고    scopus 로고
    • Current therapy for multiple myeloma
    • Rajkumar SV, Gertz MA, Kyle RA, Greipp PR, Mayo Clinic Myeloma, Amyloid, and Dysproteinemia Group. Current therapy for multiple myeloma. Mayo Clin Proc. 2002;77:813-822.
    • (2002) Mayo Clin Proc , vol.77 , pp. 813-822
    • Rajkumar, S.V.1    Gertz, M.A.2    Kyle, R.A.3    Greipp, P.R.4
  • 49
    • 0037216013 scopus 로고    scopus 로고
    • Multiple myeloma: How far have we come?
    • Anderson KC. Multiple myeloma: how far have we come? [editorial]. Mayo Clin Proc. 2003;78:15-17.
    • (2003) Mayo Clin Proc , vol.78 , pp. 15-17
    • Anderson, K.C.1
  • 50
    • 0037216353 scopus 로고    scopus 로고
    • Review of 1027 patients with newly diagnosed multiple myeloma
    • Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21-33.
    • (2003) Mayo Clin Proc , vol.78 , pp. 21-33
    • Kyle, R.A.1    Gertz, M.A.2    Witzig, T.E.3
  • 51
    • 0035881127 scopus 로고    scopus 로고
    • Thalidomide in the treatment of plasma cell malignancies
    • Rajkumar SV, Kyle RA. Thalidomide in the treatment of plasma cell malignancies [editorial]. J Clin Oncol. 2001;19:3593-3595.
    • (2001) J Clin Oncol , vol.19 , pp. 3593-3595
    • Rajkumar, S.V.1    Kyle, R.A.2
  • 52
    • 0034655161 scopus 로고    scopus 로고
    • Thalidomide: Current and potential clinical applications
    • Calabrese L, Fleischer AB. Thalidomide: current and potential clinical applications. Am J Med. 2000;108:487-495.
    • (2000) Am J Med , vol.108 , pp. 487-495
    • Calabrese, L.1    Fleischer, A.B.2
  • 53
  • 54
    • 0034554739 scopus 로고    scopus 로고
    • Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia
    • Tefferi A, Elliot MA. Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia [letter]. Blood. 2000;96:4007.
    • (2000) Blood , vol.96 , pp. 4007
    • Tefferi, A.1    Elliot, M.A.2
  • 55
    • 0012889254 scopus 로고    scopus 로고
    • A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia
    • Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2003;101:2534-2541.
    • (2003) Blood , vol.101 , pp. 2534-2541
    • Mesa, R.A.1    Steensma, D.P.2    Pardanani, A.3
  • 56
    • 0036243117 scopus 로고    scopus 로고
    • Thalidomide treatment in myelofibrosis with myeloid metaplasia
    • Elliott MA, Mesa RA, Li CY, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol. 2002;117:288-296.
    • (2002) Br J Haematol , vol.117 , pp. 288-296
    • Elliott, M.A.1    Mesa, R.A.2    Li, C.Y.3
  • 57
    • 0035669269 scopus 로고    scopus 로고
    • The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes
    • Zorat F, Shetty V, Dutt D, et al. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol. 2001;115:881-894.
    • (2001) Br J Haematol , vol.115 , pp. 881-894
    • Zorat, F.1    Shetty, V.2    Dutt, D.3
  • 58
    • 0035883101 scopus 로고    scopus 로고
    • Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes
    • Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood. 2001;98:958-965.
    • (2001) Blood , vol.98 , pp. 958-965
    • Raza, A.1    Meyer, P.2    Dutt, D.3
  • 59
    • 0033916672 scopus 로고    scopus 로고
    • Activity of thalidomide in AIDS-related Kaposi's sarcoma
    • Little RF, Wyvill KM, Pluda JM, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol. 2000;18:2593-2602.
    • (2000) J Clin Oncol , vol.18 , pp. 2593-2602
    • Little, R.F.1    Wyvill, K.M.2    Pluda, J.M.3
  • 60
    • 0442305232 scopus 로고    scopus 로고
    • Phase II study of thalidomide + interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma (MRCC)
    • Abstract 1556
    • Amato RJ, Schell J, Thompson N, Moore R, Miles B. Phase II study of thalidomide + interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma (MRCC) [abstract]. Prog Proc Am Soc Clin Oncol. 2003;22:387. Abstract 1556.
    • (2003) Prog Proc Am Soc Clin Oncol , vol.22 , pp. 387
    • Amato, R.J.1    Schell, J.2    Thompson, N.3    Moore, R.4    Miles, B.5
  • 61
    • 0036139999 scopus 로고    scopus 로고
    • Phase II trial of thalidomide for patients with advanced renal cell carcinoma
    • Motzer RI, Berg W, Ginsberg M, et al. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol. 2002;20:302-306.
    • (2002) J Clin Oncol , vol.20 , pp. 302-306
    • Motzer, R.I.1    Berg, W.2    Ginsberg, M.3
  • 62
    • 0035990828 scopus 로고    scopus 로고
    • Phase II trial of thalidomide in renal-cell carcinoma
    • Escudier B, Lassau N, Couanet D, et al. Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol. 2002;13:1029-1035.
    • (2002) Ann Oncol , vol.13 , pp. 1029-1035
    • Escudier, B.1    Lassau, N.2    Couanet, D.3
  • 65
    • 0035927983 scopus 로고    scopus 로고
    • Deep vein thrombosis and thalidomide therapy for multiple myeloma
    • Osman K, Comenzo R, Rajkumar SV. Deep vein thrombosis and thalidomide therapy for multiple myeloma [letter]. N Engl J Med. 2001;344:1951-1952.
    • (2001) N Engl J Med , vol.344 , pp. 1951-1952
    • Osman, K.1    Comenzo, R.2    Rajkumar, S.V.3
  • 66
    • 0035469858 scopus 로고    scopus 로고
    • Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy
    • Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98:1614-1615.
    • (2001) Blood , vol.98 , pp. 1614-1615
    • Zangari, M.1    Anaissie, E.2    Barlogie, B.3
  • 67
    • 0037103292 scopus 로고    scopus 로고
    • Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: Implications for therapy
    • Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002;100:1168-1171.
    • (2002) Blood , vol.100 , pp. 1168-1171
    • Zangari, M.1    Siegel, E.2    Barlogie, B.3
  • 68
    • 0036526384 scopus 로고    scopus 로고
    • Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications
    • Zangari M, Saghafifar F, Anaissie E, et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis. 2002;13:187-192.
    • (2002) Blood Coagul Fibrinolysis , vol.13 , pp. 187-192
    • Zangari, M.1    Saghafifar, F.2    Anaissie, E.3
  • 69
    • 0034727058 scopus 로고    scopus 로고
    • Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma
    • Rajkumar SV, Gertz MA, Witzig TE. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma [letter]. N Engl J Med. 2000;343:972-973.
    • (2000) N Engl J Med , vol.343 , pp. 972-973
    • Rajkumar, S.V.1    Gertz, M.A.2    Witzig, T.E.3
  • 70
    • 0036532258 scopus 로고    scopus 로고
    • Hypothyroidism in patients with multiple myeloma following treatment with thalidomide
    • Badros AZ, Siegel E, Bodenner D, et al. Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. Am J Med. 2002;112:412-413.
    • (2002) Am J Med , vol.112 , pp. 412-413
    • Badros, A.Z.1    Siegel, E.2    Bodenner, D.3
  • 71
    • 0034063332 scopus 로고    scopus 로고
    • Pharmacology of thalidomide
    • Stirling DI. Pharmacology of thalidomide. Semin Hematol. 2000;37(suppl 3):5-14.
    • (2000) Semin Hematol , vol.37 , Issue.SUPPL. 3 , pp. 5-14
    • Stirling, D.I.1
  • 72
    • 0028916174 scopus 로고
    • Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide
    • Eriksson T, Bjorkman S, Roth B, Fyge A, Hoglund P. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality. 1995;7:44-52.
    • (1995) Chirality , vol.7 , pp. 44-52
    • Eriksson, T.1    Bjorkman, S.2    Roth, B.3    Fyge, A.4    Hoglund, P.5
  • 73
    • 0033168605 scopus 로고    scopus 로고
    • Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha
    • Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163:380-386.
    • (1999) J Immunol , vol.163 , pp. 380-386
    • Corral, L.G.1    Haslett, P.A.2    Muller, G.W.3
  • 74
    • 0033200056 scopus 로고    scopus 로고
    • Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients
    • Haslett PA, Klausner JD, Makonkawkeyoon S, et al. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res Hum Retroviruses. 1999;15:1169-1179.
    • (1999) AIDS Res Hum Retroviruses , vol.15 , pp. 1169-1179
    • Haslett, P.A.1    Klausner, J.D.2    Makonkawkeyoon, S.3
  • 75
    • 0035412366 scopus 로고    scopus 로고
    • Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
    • Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210-216.
    • (2001) Blood , vol.98 , pp. 210-216
    • Davies, F.E.1    Raje, N.2    Hideshima, T.3
  • 76
    • 0034331194 scopus 로고    scopus 로고
    • Thalidomide and its analogs overcome drug resistance of multiple myeloma cells to conventional therapy
    • Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of multiple myeloma cells to conventional therapy. Blood. 2000;96:2943-2950.
    • (2000) Blood , vol.96 , pp. 2943-2950
    • Hideshima, T.1    Chauhan, D.2    Shima, Y.3
  • 78
    • 0035211277 scopus 로고    scopus 로고
    • Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma
    • D'Amato RJ, Lentzsch S, Anderson KC, Rogers MS. Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. Semin Oncol. 2001;28:597-601.
    • (2001) Semin Oncol , vol.28 , pp. 597-601
    • D'Amato, R.J.1    Lentzsch, S.2    Anderson, K.C.3    Rogers, M.S.4
  • 79
    • 0036624741 scopus 로고    scopus 로고
    • Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: Therapeutic applications
    • Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002;99:4079-4086.
    • (2002) Blood , vol.99 , pp. 4079-4086
    • Mitsiades, N.1    Mitsiades, C.S.2    Poulaki, V.3
  • 80
    • 85030883440 scopus 로고    scopus 로고
    • Joslin K, Egle S, Herried M, et al. Chirality. Available at: www.uwstout .edu/artsci/mscs/deckelmans/2001-02/Fall%202001/chirality.ppt. Accessibility verified May 14, 2004.
    • Chirality
    • Joslin, K.1    Egle, S.2    Herried, M.3
  • 81
    • 0036839013 scopus 로고    scopus 로고
    • Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
    • Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063-3067.
    • (2002) Blood , vol.100 , pp. 3063-3067
    • Richardson, P.G.1    Schlossman, R.L.2    Weller, E.3
  • 82
    • 1842619774 scopus 로고    scopus 로고
    • A multi-center, randomized, phase 2 study to evaluate the efficacy and safety of 2 CDC-5013 dose regimens when used alone or in combination with dexamethasone (Dex) for the treatment of relapsed or refractory multiple myeloma (MM)
    • Abstract 825
    • Richardson PG, Jagannath S, Schlossman R, et al. A multi-center, randomized, phase 2 study to evaluate the efficacy and safety of 2 CDC-5013 dose regimens when used alone or in combination with dexamethasone (Dex) for the treatment of relapsed or refractory multiple myeloma (MM) [abstract]. Blood. 2003;102(pt 1):235a. Abstract 825.
    • (2003) Blood , vol.102 , Issue.PART 1
    • Richardson, P.G.1    Jagannath, S.2    Schlossman, R.3
  • 83
    • 0003234481 scopus 로고    scopus 로고
    • Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT)
    • Abstract 3226
    • Zangari M, Tricot G, Zeldis J, Eddlemon P, Saghafifar F, Barlogie B. Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT) [abstract]. Blood. 2001;98 (pt 1):775a. Abstract 3226.
    • (2001) Blood , vol.98 , Issue.PART 1
    • Zangari, M.1    Tricot, G.2    Zeldis, J.3    Eddlemon, P.4    Saghafifar, F.5    Barlogie, B.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.